匯思太平洋(08147.HK)延長認購深圳市媒訊隴峯科技股份盡職審查期
格隆匯3月2日丨匯思太平洋(08147.HK)公佈,於2019年12月2日,公司與深圳市媒訊投資控股有限公司訂立不具法律約束力諒解備忘錄。根據諒解備忘錄,待訂立正式協議後,公司將通過其於中國註冊成立的全資附屬公司透過認購深圳市媒訊隴峯科技有限公司(目標公司)股權而以注資形式作出投資,相當於注資後目標公司註冊資本的51%。
由於近期爆發新型冠狀病毒(COVID-19),多個省市已實施旅遊限制,且為保障集團員工的健康與安全,經與深圳媒訊投資商討後,雙方協定將盡職審查期延長至2020年9月1日(或公司與深圳媒訊投資經考慮病毒傳播情況及對盡職審查的影響後所協定的較後日期)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.